Zoetis Secures FDA Emergency Nod for Livestock Injection While Insiders Snap Up Shares at Steep Discount

Zoetis receives FDA approval for Dectomax-Ca1 livestock drug, but stock falls 37% after Q1 earnings miss and pet health headwinds. Insiders buy $900k in shares, analysts see value despite cuts.

The animal health giant Zoetis finds itself in an unusual position: advancing on a regulatory front even as its stock suffers one of its worst routs in years. The company received an emergency use authorization from the U.S. Food and Drug Administration for Dectomax-Ca1 injectable solution on Tuesday, a move that bolsters its cattle and swine product line just as investor sentiment hits a low ebb.

The timing of the FDA nod is notable. Zoetis shares have shed roughly 37% since the start of 2026, with the monthly decline alone touching 35%. The stock now trades at €67.34, a fraction of its 52-week high near €150. The 200-day moving average sits around €110, meaning the current price is about 38% below that benchmark.

Insiders back the battered stock

Against this backdrop of deep losses, several board members have stepped up to buy shares. Michael B. McCallister acquired 3,000 shares, while Frank A. Damelio picked up 6,650. Insider purchases over the past three months have totalled nearly $900,000 — a clear vote of confidence from those closest to the company’s strategy.

Institutional investors are sending mixed signals. The North Dakota State Investment Board built a new position on Tuesday, buying over 15,000 shares. At the same time, iA Global Asset Management reduced its stake, while Thrivent Financial significantly increased its holdings. The divergence underscores the uncertainty surrounding Zoetis’ near-term trajectory.

Earnings disappointment triggered the slide

The selling pressure can be traced back to the first-quarter results. Revenue edged up to $2.26 billion, but earnings per share of $1.53 fell short of the $1.60 consensus. Management responded by trimming the full-year outlook. Revenue is now forecast to land between $9.68 billion and $9.96 billion, with organic growth of 2% to 5%. Adjusted earnings per share are expected in a range of $6.85 to $7.00.

The primary culprit is the U.S. pet health market, where generic competition and shifting consumer spending patterns have squeezed margins. That segment has been dragging on overall profitability, forcing the company to lean harder on its livestock business. The U.S. cattle and swine unit posted 7% revenue growth in the most recent quarter, providing a measure of stability.

Analyst targets come down, but buy ratings stay

Wall Street has recalibrated its expectations. Citigroup lowered its price target to $112 from $145 while keeping a buy rating. Morgan Stanley cut its target to $115 from $160 but maintained an overweight stance. Both firms see the stock as attractively valued after the steep decline, even if short-term headwinds persist. The consensus analyst rating currently sits at “hold,” with an average 12-month target of $134.75.

Genomics acquisition and dividend offer forward catalysts

Zoetis is also working to close its acquisition of Neogen’s genomic technologies, expected in the second half of 2026. The deal aims to expand the company’s precision livestock offerings through data analytics and predictive tools for farmers and ranchers.

Meanwhile, the board has proposed a quarterly dividend of $0.53 per share for the second quarter, with payment planned for June. That payout, combined with the FDA approval and the strategic push into genomics, gives the market tangible developments to weigh against the current turbulence. Ultimately, whether Zoetis can restore confidence will hinge on how quickly it can stabilise margins in its U.S. pet business and sustain the upward momentum in its livestock segment.